Ecopipam - Emalex Biosciences
Alternative Names: EBS-101; Ecopipam HCl; Ecopipam Hydrochloride; PSYRX 101; SCH-39166Latest Information Update: 28 Jun 2024
At a glance
- Originator Schering-Plough
- Developer Emalex Biosciences; Psyadon Pharmaceuticals; Schering-Plough
- Class Alcohols; Antipsychotics; Behavioural disorder therapies; Benzazepines; Cardiovascular therapies; Chlorinated hydrocarbons; Drug withdrawal therapies; Heterocyclic compounds with 4 or more rings; Naphthalenes; Obesity therapies; Small molecules
- Mechanism of Action Dopamine D1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome
- Phase II Speech disorders
- Phase I/II Restless legs syndrome
- Phase I Cardiovascular disorders
- No development reported Gambling
- Discontinued Cocaine-related disorders; Obesity; Schizophrenia
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Lesch-Nyhan-syndrome(In volunteers) in United Kingdom (PO, Controlled release)
- 27 May 2024 Efficacy data from a phase I trial in Speech disorders released by Emalex Biosciences
- 13 Apr 2024 Updated efficacy data from a phase IIb D1AMOND trial Gilles de la Tourette's syndrome presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)